GERMANY - TVM Capital backs Riemser Arzneimittel AG
Munich and Boston-based TVM Capital has invested an undisclosed sum in Riemser Arzneimittel AG. TVM Capital now holds 10% of the Riemser AG shares. TMV Capitals plans to help transition and grow Riemser Arzneimittel AG into an international corporation. Riemser Arzneimittel AG is a midsized pharmaceutical company on the island of Riems in Mecklenburg-Vorpommern, Germany. It has 450 employees at four manufacturing plants with annual revenues of about EUR 56m. The company develops and produces a line of successful dermatology, cardiovascular and anti-inflammatory, oncology and dental care pharmaceuticals.
More on Expansion
Blackstone takes minority stake in Groupe Premium
Deal values French wealth manager at EUR 1.15bn after earlier full exit attempt saw Eurazeo target EUR 1.5bn
e-Attestations aims to triple size with new Keensight backing
Keensight is investing in the risk management platform via its EUR 1bn fifth fund, which closed in 2019
The Bolt-Ons Digest - 3 July 2023
Unquote’s selection of the latest add-ons with Palatine's Anthesis, Nordic Capital's Regnology, Waterland's Janssen and more
GP Profile: Limerston Capital anticipates higher volume but more complex M&A as market steadies
UK-based GP is seeing dealflow driven by carve-outs and buy-and-build in a market where organic multiple arbitrage is no longer a given
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater